A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...
Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at ...
New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...
Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...
The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...
A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...
Winship Cancer Institute of Emory University, a nonprofit medical research center based out of Atlanta, has launched a new mobile prostate cancer screening program. Backed by the Arthur M. Blank ...
During last night's game presented by Emory Healthcare, the Atlanta Hawks Foundation, together with the Ressler Gertz Family Foundation, announced a $150,000 donation to the Prostate Cancer Foundation ...
Don Bryant, Indiana resident, U.S. Army veteran, and prostate cancer survivor who received treatment with Pluvicto™ therapy in clinical trial Philip Low, Purdue Institute for Cancer Research member, ...
From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...
Doug pedals fast, feeling the exhilaration of speeding along a bike track as his heart rate rises and he starts to breathe harder. Since being diagnosed with stage 4 metastatic prostate cancer in ...
A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...